Quoin Pharmaceuticals, LTD 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Quoin Pharmaceuticals reports significant clinical progress for its lead Netherton Syndrome drug QRX003, including positive Phase 2 data and FDA openness to pivotal study design, despite ongoing substantial net losses and a going concern warning.
NASDAQ
Quoin Pharmaceuticals reports its 10-K filing, highlighting ongoing clinical trials for QRX003 in Netherton Syndrome, but also significant losses and the need for additional capital.
NASDAQ
Quoin Pharmaceuticals' annual report on Form 10-K provides a detailed overview of the company's share structure, voting rights, and compliance with securities regulations.